Novo, formerly known as Novo Nordisk, signed a licensing deal Friday with Sweden's Nanexa worth up to $1.3 billion to develop long-acting injectable drugs for cardiometabolic diseases.
Why it matters: As obesity pipelines grow more crowded, drugmakers are looking for new ways to differentiate.
